| Literature DB >> 31660633 |
Peter C Austin1,2,3, Aurélien Latouche4,5, Jason P Fine6,7.
Abstract
In survival analysis, time-varying covariates are covariates whose value can change during follow-up. Outcomes in medical research are frequently subject to competing risks (events precluding the occurrence of the primary outcome). We review the types of time-varying covariates and highlight the effect of their inclusion in the subdistribution hazard model. External time-dependent covariates are external to the subject, can effect the failure process, but are not otherwise involved in the failure mechanism. Internal time-varying covariates are measured on the subject, can effect the failure process directly, and may also be impacted by the failure mechanism. In the absence of competing risks, a consequence of including internal time-dependent covariates in the Cox model is that one cannot estimate the survival function or the effect of covariates on the survival function. In the presence of competing risks, the inclusion of internal time-varying covariates in a subdistribution hazard model results in the loss of the ability to estimate the cumulative incidence function (CIF) or the effect of covariates on the CIF. Furthermore, the definition of the risk set for the subdistribution hazard function can make defining internal time-varying covariates difficult or impossible. We conducted a review of the use of time-varying covariates in subdistribution hazard models in articles published in the medical literature in 2015 and in the first 5 months of 2019. Seven percent of articles published included a time-varying covariate. Several inappropriately described a time-varying covariate as having an association with the risk of the outcome.Entities:
Keywords: competing risks; subdistribution hazard model; survival analysis; time-varying covariate
Year: 2019 PMID: 31660633 PMCID: PMC6916372 DOI: 10.1002/sim.8399
Source DB: PubMed Journal: Stat Med ISSN: 0277-6715 Impact factor: 2.373
Papers reporting time‐varying covariates in a Fine‐Gray subdistribution hazard model
|
|
|
|
|
|
|---|---|---|---|---|
|
|
| |||
| Han et al | Cervical cancer‐ | Death from other | Cumulative dose | |
| specific mortality | causes | of metformin | ||
| after cervical | ||||
| cancer diagnosis | ||||
| Ong et al | Death | Discharge from | The occurrence | |
| the ICU | of a specific | |||
| infection | ||||
| Dautzenberg et al | ICU mortality | ICU discharge | Colonization by | |
| a specific organism | ||||
| Vajdic et al | Cause‐specific | Deaths from | Specific | Age, calendar |
| mortality | other causes | infections and | year of follow‐ | |
| undergoing | up, and number | |||
| opioid | of episodes of | |||
| substitution | opioid | |||
| therapy | substitution | |||
| therapy | ||||
| Ong et al | Mortality | Liberation from | Viral reactivation | |
| mechanical | status | |||
| ventilator | ||||
| support | ||||
| Klein Hesselink et al | Atrial fibrillation | All‐cause | Use of neck | Cumulative |
| mortality | radiotherapy | thyroid | ||
| stimulating | ||||
| hormone level | ||||
| and radioiodine dose | ||||
| Aksnessaether et al | Second cancer | Death | Treatment | |
| Li et al | Acute coronary | Death | Antiviral | |
| syndrome/end‐ | treatment | |||
| stage renal | ||||
| disease/ischaemic | ||||
| stroke/retinopathy | ||||
| Deka et al | Development of | Death | Androgen | |
| depression | deprivation | |||
| therapy | ||||
| Mori et al | TCZ | TCZ | Clinical Disease | |
| discontinuation | discontinuation | Activity Index | ||
| due to secondary | due to remission | (as binary or | ||
| loss of efficacy | or other reasons | categorical | ||
| variable) | ||||
| Yaffe et al | Dementia | Death | Number of | |
| follow‐up visits | ||||
| per year |